Bristol Myers reports new four-year Sotyktu data

Bristol Myers Squibb announced new four-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. After four years of continuous treatment, Week 208 responses for Psoriasis Area and Severity Index 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% for static Physician’s Global Assessment 0/1, using modified nonresponder imputation. The safety profile of Sotyktu at Year 4 remained consistent with the established safety profile, with no new safety signals identified, the company said. These data were presented at the European Academy of Dermatology and Venereology, or EADV, Spring Symposium in St. Julian’s, Malta taking place May 16-18, the company noted.